There are new adjustments to the HPV vaccine immunization schedule in many places! These people can take one less shot

　　The Zhejiang Provincial Center for Disease Control and Prevention released official news on March 15 that there have been new adjustments to the HPV vaccine immunization program.

　　The main change in this adjustment is for females aged 9-14. The original 3-dose immunization schedule for bivalent and 9-valent vaccines has been updated to a choice of 2 or 3 doses.

If you choose 2 doses of vaccination, that is, 1 dose in 0 and 6 months respectively, with an interval of not less than 5 months.

　　It should be emphasized that women aged 15-45 years old can still only choose the 3-dose vaccination schedule.

In addition, among the HPV vaccines currently on the market, the quadrivalent vaccine requires 3 doses to complete the full course of immunity.

　　In addition to the Zhejiang Provincial Center for Disease Control and Prevention, the Municipal Centers for Disease Control and Prevention in Dalian, Harbin and other places have also recently updated their HPV vaccine vaccination plans. Women in younger ages (9-14 years old) can choose between bivalent and nine-valent HPV vaccines. Two-shot regimen.

　　In fact, although the current immunization schedule in the instructions for bivalent and nonavalent vaccines is still 3 doses, it is a general consensus among experts in the industry to vaccinate girls aged 9-14 with 2 doses of HPV vaccine.

Zou Shien, chief physician of the Obstetrics and Gynecology Hospital of Fudan University, told China Business News last year: "According to the current HPV vaccine immunization schedule, three injections are given, and teenagers aged 9-14 can get two injections."

　　However, more and more clinical data have recently shown that the HPV vaccine can still provide immune protection three years after the first dose of vaccination.

So for women aged 15-45, can the second and third shots be postponed and wait until the immune protection has weakened before taking the second and third shots?

　　In this regard, an HPV vaccine researcher told China Business News: "The currently recognized clinical results and instructions recommend a three-shot vaccination program, which requires three shots to be completed within six months, with an interval of three months. Personally It is believed that it is still necessary to take a second booster shot, which can be given within 6 months after the first shot, and whether to take the third shot can be a personal choice."

　　In recent years, the World Health Organization has begun to advocate reducing the number of HPV vaccine doses, recommending that countries should provide one or two doses of the vaccine to women aged 9 to 20 years old.

Recently, Merck also announced the launch of a single-dose clinical trial of the nine-valent HPV vaccine to evaluate the effectiveness and safety of a single-dose HPV vaccine in men and women aged 16 to 26 years.

　　HPV is one of the common viruses that infect humans and is also an important cause of cervical cancer.

There are more than 200 subtypes of HPV, but not all subtypes can cause cervical cancer. Clinically, they are divided into high-risk types and low-risk types based on their carcinogenicity. Persistent infection with high-risk HPV is the highest risk factor for cervical cancer. factor.

Among high-risk HPV types, cervical cancer caused by types 16 and 18 account for 70% of cervical cancers related to HPV infection.

　　Data shows that women who have normal sexual behavior have an 80% chance of being infected with at least one type of HPV in their lifetime, but most are asymptomatic transient infections that can be cleared by the autoimmune system within 6-18 months.

　　There are currently bivalent, quadrivalent and nine-valent HPV vaccines on the market.

The bivalent HPV vaccine can prevent HPV types 16 and 18; the quadrivalent HPV vaccine can prevent HPV types 6, 11, 16, and 18; the nine-valent HPV vaccine has wider prevention coverage and can prevent types 6, 18, and 18. HPV types 11, 16, 18, 31, 33, 45, 52, and 58.

Among the various types of HPV vaccines already on the market, except for a few bivalent vaccines that are suitable for women aged 9-30, the rest can be applied to women aged 9-45.

　　Research shows that the bivalent and quadrivalent vaccines can protect 98% to 100% of high-grade cervical, vaginal and vulvar lesions caused by HPV16/18; while the nine-valent vaccine can also prevent about 97% of high-grade lesions caused by HPV31/33/45 High-grade lesions of the cervix, vagina and vulva caused by /52/58.

　　Source: China Business News